Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
Abstract Background The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimer...
Main Authors: | Mariella Dono, Giuseppa De Luca, Sonia Lastraioli, Giorgia Anselmi, Maria Giovanna Dal Bello, Simona Coco, Irene Vanni, Francesco Grossi, Antonella Vigani, Carlo Genova, Manlio Ferrarini, Jean Louis Ravetti, Simona Zupo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Molecular Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10020-019-0082-5 |
Similar Items
-
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
by: Saad N, et al.
Published: (2017-03-01) -
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01) -
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01) -
Performance of the Oncomine<sup>TM</sup> Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice
by: Giuseppa De Luca, et al.
Published: (2020-04-01) -
Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)